Loading...
Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
BACKGROUND: Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of functional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administered either intravenously (intravenous immunoglobulin [IVIG]) or subcutaneously...
Na minha lista:
| Udgivet i: | BMC Immunol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7197164/ https://ncbi.nlm.nih.gov/pubmed/32366233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12865-020-00346-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|